ENTERO
Entero Healthcare Solutions Limited (entero) Q1 FY27: Revenue Up 38% Yoy, Margins Improve
Entero Healthcare Solutions Limited (ENTERO) reports a 38% YoY revenue growth and improved margins for Q1 FY27.
Entero Healthcare Solutions Limited (ENTERO) has announced its financial results for Q1 FY27, marking a robust start to the fiscal year with a consolidated revenue growth of 40.0% year-on-year on a like-for-like basis to INR 1,940 crore. The company also saw a significant improvement in EBITDA margins reaching 5.0%.
Revenue and Margin Growth
The revenue growth on a like-for-like basis was 40.0% year-on-year. Organic revenue growth on a like-for-like basis was 19.6% year-on-year. The company’s gross margin improved by 147 basis points year-on-year to 11.4%. EBITDA margin improved by 143 basis points year-on-year to 5.0%.
Return Ratios
Return on Capital Employed (RoCE) nearly doubled year-on-year to 21.1% and Return on Equity (ROE) to 20.4%. These improvements set a strong momentum for the rest of the year, with high confidence on delivering on the company’s guidance.
As Prabhat Agrawal, Promoter, MD, and CEO, stated, ‘We have started FY27 on a strong footing with consolidated revenue growth of 40.0% YoY on a like-for-like basis to INR 1,940 crore alongside further margin improvement with EBITDA margins reaching 5.0%.’
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Entero Healthcare Solutions Limited
Entero Healthcare Solutions Limited belongs to the Healthcare › Medical Distribution sector. Here’s a quick read on where the business and the stock stand today.
Entero holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 67% of its 52-week range with RSI at 54. In other words, neither side has a clear edge right now. Revenue grows at 25.7% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Entero Healthcare Solutions Limited.
ENTERO
Entero Healthcare Solutions Limited (NSE: ENTERO) breaks out, moves up 5% intraday
Entero Healthcare Solutions Limited (NSE: ENTERO) stock breaks out with a 5% intraday gain, clearing its 6M resistance trendline. Current price at ₹1392.5.
Entero Healthcare Solutions Limited (ENTERO) breaks out, gaining +5% to ₹1392.5 on the NSE on 11 Aug 2026. The stock cleared its 6-month resistance trendline, signaling a breakout after approaching resistance. Entero operates in the healthcare sector, specifically medical distribution, and today’s move appears company-specific rather than a sector-wide trend.
Technical setup — trendlines & DMA
The current 6-month trendline structure shows Entero’s stock breaking out above the resistance trendline at ₹1221, which is now 12.3% below the current price. The 6-month support trendline ends at ₹1262.35, which is 9.35% below the current price. The stock is trading 11% above the 50-DMA at ₹1183.4 and 14.98% above the 200-DMA at ₹1143.8, indicating a stretched move. The stock is currently in the upper third of its 52-week range of ₹944.0 to ₹1426.3, suggesting that a substantial portion of the move is already priced in.
Snapshot: ₹1,392.50 on 2026-08-11 (chart frozen at publication)
Fundamentals & business context
With a PE of 49.9 and profit margins at 1.8%, Entero’s valuation appears stretched relative to its current earnings, despite a robust revenue CAGR of 25.7% over the past five years. The 15.0% institutional ownership suggests that smart money is cautiously optimistic but not overly bullish on the stock. There is no specific NSE catalyst today driving the move, but the breakout and strong technical indicators are likely contributing to the positive sentiment.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally weak profile for Entero. The strongest signals include the excellent revenue CAGR of 25.7%, indicating strong business growth, and the very low debt level with a D/E ratio of 0.22, suggesting excellent financial health. On the weaker side, the 1.8% profit margin leaves little room for error, and the negligible dividend yield of 0% offers little income to investors. These factors highlight the risks associated with the stock’s valuation and income generation.
Company outlook
Entero Healthcare Solutions Limited is aiming for consolidated revenue growth of 23% year-on-year for FY27, with a focus on profitable revenue growth and operational efficiencies to drive margins. Management expects an EBITDA margin of 5% and an EBITDA to operating cash flow conversion ratio of at least 50% for FY27. The tax rate is expected to be in the range of 22% to 23%, and minority interest is projected to be around 25% to 27% of PAT before minority interest. Working capital as a percentage of sales is expected to decrease directionally. The company plans to focus on organic growth for the next 6 to 8 months, aiming for an EBITDA to operating cash flow conversion ratio of at least 50% to ensure sustainable growth.
Get all details on ENTERO — P&L, peers, shareholding and more on TradeAlone.
ENTERO
Entero Healthcare Solutions Limited (ENTERO) gains 10% intraday
Entero Healthcare Solutions Limited (NSE: ENTERO) stock price moves up 10% intraday to ₹1379.0, clearing resistance at ₹1221 by 11.5%.
Entero Healthcare Solutions Limited (ENTERO) gained +10% today, driven by the release of its unaudited financial results for the quarter ended June 30, 2026. The stock has cleared a key resistance level at ₹1221, marking an 11.5% breakout. Entero operates in the healthcare sector, specifically medical distribution, and today’s move appears to be company-specific rather than a sector-wide trend.
Technical setup — trendlines & DMA
From a technical perspective, ENTERO has broken above its 6-month resistance trendline, which ended at ₹1220.67, indicating a bullish breakout. The stock is currently trading 11.48% above this resistance level. The 6-month support trendline is at ₹1262.35, and the stock is 8.46% above this level, suggesting strong upward momentum. The 50-day moving average (DMA) is at ₹1181.4, above the 200-DMA at ₹1142.5, signaling a positive trend. The stock is in the upper third of its 52-week range, indicating that much of the recent price action is already reflected in the current level.
Snapshot: ₹1,379.00 on 2026-08-10 (chart frozen at publication)
Fundamentals & business context
Fundamentally, ENTERO’s PE of 47.0, coupled with a profit margin of 1.7%, suggests that the market is pricing in significant growth expectations despite current thin margins. The revenue CAGR of 25.7% over the past five years indicates strong top-line growth, but the absence of profit CAGR raises questions about profitability. Institutional ownership stands at 15.0%, which is moderate, suggesting that while there is some institutional interest, it is not overwhelmingly positive. There was no specific NSE catalyst today beyond the financial results release.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally weaker position for ENTERO. The strongest signals include the excellent revenue CAGR of 25.7%, indicating robust growth, and the very low debt level with a D/E ratio of 0.22, which points to strong financial health. On the weaker side, the low profit margin of 1.7% leaves little room for error, and the negligible dividend yield of 0% means there is little income generation for investors. These factors highlight the need for careful consideration of the stock’s growth trajectory versus its current valuation.
Company outlook
Management has outlined an ambitious forward guidance for FY27, aiming for consolidated revenue growth of 23% year-on-year, excluding any new acquisitions, with an EBITDA margin target of 5%. The focus will be on profitable revenue growth and operational efficiencies to drive margins. Management expects the EBITDA to operating cash flow conversion ratio to be at least 50% for FY27, with a tax rate in the range of about 22% – 23%. Minority interest is expected to be around 25% to 27% of PAT before minority interest. Working capital as a percentage of sales is expected to decrease directionally. The company plans to focus on organic growth for the next 6 to 8 months, aiming for an EBITDA to operating cash flow conversion ratio of at least 50% to ensure sustainable growth.
Get all details on ENTERO — P&L, peers, shareholding and more on TradeAlone.
ENTERO
Entero Healthcare Solutions Limited (NSE: ENTERO) clears resistance at ₹1221, gains 8% intraday
Entero Healthcare Solutions Limited (NSE: ENTERO) stock has cleared resistance at ₹1221, gaining 8% intraday. The stock is now trading at ₹1345.0.
Entero Healthcare Solutions Limited (ENTERO) gained +8% to ₹1345.0 on the NSE on 10 Aug 2026. The stock moved today following the release of its unaudited financial results for the quarter ended June 30, 2026, as per the NSE filing. Entero Healthcare, a key player in the medical distribution sector, has shown a breakout above its 6-month resistance trendline at ₹1221, indicating strong momentum. This move aligns with the company’s robust revenue growth trajectory, although it stands out as more company-specific given the sector’s mixed performance.
Technical setup — trendlines & DMA
The current 6-month trendline structure shows a breakout above the resistance trendline at ₹1221, with the stock now trading 9.2% above this level. The 6-month support trendline stands at ₹1262.35, which is 6.14% below today’s price, providing a solid floor. The 50-DMA at ₹1181.4 is above the 200-DMA at ₹1142.5, signaling a bullish trend. The stock is trading well above both moving averages, indicating strong upward momentum. In the 52-week range of ₹944.0–₹1390.0, the current price is in the upper third, suggesting that a significant portion of the expected move is already priced in, though there is still some room for further upside.
Snapshot: ₹1,345.00 on 2026-08-10 (chart frozen at publication)
Fundamentals & business context
With a PE of 47.0 and profit margins at 1.7%, Entero Healthcare’s valuation appears stretched relative to its current earnings, especially given the thin profit margins. However, the revenue CAGR of 25.7% over the past five years suggests that the market may be pricing in future growth potential. The 15.0% institutional ownership indicates a cautious yet interested stance from smart money, possibly betting on the company’s growth prospects. There was no specific NSE catalyst today beyond the regular financial disclosures, but the consistent revenue growth and strategic outlook provide a foundation for the stock’s performance.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally weak profile for Entero Healthcare. Two of the strongest signals are the excellent revenue CAGR of 25.7% and the very low debt levels with a D/E ratio of 0.22, indicating robust growth and solid financial health. On the flip side, the two weakest signals are the low profit margin of 1.7% and the negligible dividend yield of 0%, which pose risks in terms of profitability and income generation for investors. The balanced ownership structure with 21.99% public ownership and the consistent revenue growth every year also contribute to a stable business outlook.
Company outlook
Entero Healthcare’s management has outlined an ambitious forward guidance for FY27, aiming for 23% year-on-year consolidated revenue growth, excluding new acquisitions, with an EBITDA margin target of 5%. The focus will be on profitable revenue growth and operational efficiencies to drive margins. Management expects the EBITDA to operating cash flow conversion ratio to be at least 50% for FY27, with a tax rate in the range of 22% – 23%. Minority interest is projected to be around 25% to 27% of PAT before minority interest. The company plans to focus on organic growth for the next 6 to 8 months, aiming for sustainable growth through a strong EBITDA to operating cash flow conversion ratio.
Get all details on ENTERO — P&L, peers, shareholding and more on TradeAlone.
-
Basic Materials3 days agoThe Ramco Cements Limited (ramcocem) Wins Three Honours at Kyoorius Design Awards 2026
-
GAIL3 days agoGail (india) Limited Appoints Shri Manoj Kumar Sharma as Director (projects)
-
COFORGE2 days agoCoforge Limited (NSE: Coforge) Expands Ai-powered Vehicle Lifecycle Intelligence Capabilities
-
Basic Materials3 days agoSteel Authority of India Limited (sail) FY’27 Snapshot: Robust Financials and Production Metrics
-
Industrials3 days agoTirupati Forge Limited Secures Strategic Industrial License Under Indian Arms Act for Artillery Shell Manufacturing
-
GODREJPROP3 days agoGodrej Properties Limited (godrejprop) Constructs 24-metre-wide Government Road in Gurugram
-
PREMIERENE1 day agoPremier Energies Limited (premierene) Commissions India’s Largest Solar Cell Facility
-
Information Technology Services20 hours agoPersistent Systems Limited (persistent) Earns Databricks Brickbuilder Specialization for BFSI